Neuropathy News and Research

RSS

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.

23 Sep 2009

Preventing nerve cell death in diabetics

Dennis Paul, PhD, Associate Professor of Pharmacology, and Harry Gould, MD, PhD, the Tom Benson Professor of Neurology at LSU Health Sciences Center New Orleans, have been awarded one of two scientific research grants made in 2009 by The Neuropathy Association. The $80,000 grant will fund research to learn how to prevent nerve cell death in people with uncontrolled or untreated diabetes resulting in neuropathy.

23 Sep 2009

Vicor's PD2i heart-rate complexity metric to be tested on trauma patients in U.S. Army's C3E program

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Colonel Leopoldo Cancio of the U.S. Army Institute of Surgical Research (USAISR) identified its PD2i as a heart rate complexity metric that will be tested on trauma patients under the new Critical Combat Care Engineering (C3E) program.

23 Sep 2009

Lundbeck offers Sabril for treating children with infantile spasms in the U.S.

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that Sabril® (vigabatrin) Tablets and Powder for Oral Solution are now available for prescribing in the United States.

22 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

Diabetic nerve pain: Most bothersome complication of diabetes

In a new online survey, eighty-five percent of people who experience diabetic nerve pain said that their pain was one of the top three most bothersome complications of their diabetes. Despite the fact that people with diabetic nerve pain recognize the condition's impact on their lives and eighty-four percent of those surveyed said they have discussed the condition with a healthcare provider, just slightly less than half of respondents (49 percent) were treating their pain.

18 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

Cytrx to submit revised protocol for arimoclomol Phase IIb clinical trial

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its planned Phase IIb clinical trial for arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The decision follows receipt of an anticipated written letter from the U.S.

8 Sep 2009

Zinc finger nucleases utilized for modifying hESCs and hiPSCs

Scientists from The Whitehead Institute used zinc finger nucleases (ZFNs) designed by Sangamo BioSciences, Inc., (Nasdaq: SGMO) to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs).

8 Sep 2009

Stemedica files patent application for diabetic retinopathy treatment

Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing, has filed a patent application with the United States Patent and Trademark Office ("USPTO") for a proprietary methodology in the treatment for Diabetic Retinopathy.

8 Sep 2009

Low HDL-cholesterol and high triglycerides linked to increased risk of CHD

Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to significantly increased risk of coronary heart disease (CHD) even in patients who achieve or surpass current low density lipoprotein cholesterol (LDL-C) targets.

3 Sep 2009

New electronic medical device for treating leg pain

ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from peripheral neuropathy and Peripheral Artery Disease today announced that it has released a new way to deliver the impulses of the ReBuilder for pain.

3 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009

New tool developed for dementia affected people

The elderly who suffer from dementia aren't able to say when something hurts or is sore. They may demonstrate their pain through behaviours like rocking or striking out, and we often dismiss these actions as symptoms of the dementia instead of pain, which is usually from a different problem. Arthritis, diabetic neuropathy, fractures, muscular contractures, bruises, abdominal pain and mouth ulcers are among the list of common ailments that go undetected.

2 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

Rebuilder Medical Technologies is in concluding stages of finalizing a national contract to provide billing services for all physicians

ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from peripheral neuropathy and Peripheral Artery Disease today announced that it is in the final stages of negotiating a national contract to provide all physicians with billing services for Medicare claims for the ReBuilder.

29 Aug 2009

ReBuilder Medical Technologies reports 100% increase in second-quarter 2009 profits over first-quarter

ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from peripheral neuropathy and Peripheral Artery Disease today announced that it has published its second quarter 09 profits and that profits are up 100% over the first quarter.

28 Aug 2009

Significant drop in prevalence of rheumatoid vasculitis between 2000 and 2001

Researchers at the University of Wisconsin School of Medicine and Public Health examined records of rheumatoid arthritis (RA) patients from the national Veterans Health Administration (VHA) system to determine the prevalence of rheumatoid vasculitis (RV) in this population. The study found a downward trend in the number of RA patients who go on to develop RV, with a significant drop of 53% among inpatients and 31% among outpatients between 2000 and 2001.

27 Aug 2009

PD2i algorithm published in Therapeutics and Clinical Risk Management can predict risk of sudden cardiac death

David H. Fater, CEO of Vicor Technologies, Inc., today announced that original research conducted using its PD2i algorithm to prospectively predict risk of sudden cardiac death was published in Therapeutics and Clinical Risk Management.

26 Aug 2009